Teriparatide is an approved prescription medicine. This page summarizes how its potential side effects are discussed and does not constitute medical advice.
Overview
As a parathyroid hormone fragment, teriparatide's side effect profile reflects its effect on bone metabolism and calcium handling. Most described effects are mild and transient, but the drug also has a notable historical safety warning that shaped how it has been used and studied.
Common effects
Commonly described effects include:
- Transient dizziness or a drop in blood pressure shortly after administration.
- Leg cramps.
- Nausea and headache.
- Injection-site reactions.
Because PTH influences calcium, changes in calcium levels are also part of what clinicians monitor.
Historical boxed warning
Teriparatide historically carried a boxed warning based on a rodent study in which some animals developed osteosarcoma (a bone cancer) with high, prolonged exposure. This finding influenced early duration limits and prescribing cautions. The human relevance has been the subject of extended follow-up research, and labeling in some regions has since been revised. The history remains relevant context for understanding how the drug has been prescribed.
General safety themes
Additional themes include cautions related to conditions that affect calcium or bone, and the general principle that anabolic bone therapy is directed at specific higher-risk situations. As with any prescription medicine, contraindications and monitoring are defined within its labeling.
Context and caveats
Teriparatide's safety is characterized within regulated osteoporosis care, where contraindications, treatment duration, and monitoring are defined. Any use should involve a prescribing clinician who can weigh individual risk factors, including calcium status and bone-related conditions, against the potential anabolic benefit.